342 related articles for article (PubMed ID: 12492111)
1. Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity.
Mashino K; Sadanaga N; Tanaka F; Ohta M; Yamaguchi H; Mori M
Mol Cancer Ther; 2002 Aug; 1(10):785-94. PubMed ID: 12492111
[TBL] [Abstract][Full Text] [Related]
2. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
3. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H
Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
[TBL] [Abstract][Full Text] [Related]
4. OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity.
Pan K; Lv L; Zheng HX; Zhao JJ; Pan QZ; Li JJ; Weng DS; Wang DD; Jiang SS; Chang AE; Li Q; Xia JC
Immunol Cell Biol; 2014 Mar; 92(3):263-74. PubMed ID: 24296809
[TBL] [Abstract][Full Text] [Related]
5. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2).
Sato M; Takayama T; Tanaka H; Konishi J; Suzuki T; Kaiga T; Tahara H
Cancer Sci; 2003 Dec; 94(12):1091-8. PubMed ID: 14662025
[TBL] [Abstract][Full Text] [Related]
6. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
Koido S; Hara E; Homma S; Torii A; Mitsunaga M; Yanagisawa S; Toyama Y; Kawahara H; Watanabe M; Yoshida S; Kobayashi S; Yanaga K; Fujise K; Tajiri H
J Immunol; 2007 Jan; 178(1):613-22. PubMed ID: 17182602
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4.
Ahmed SU; Okamoto M; Oshikawa T; Tano T; Sasai A; Kan S; Hiroshima T; Ohue H; Moriya Y; Ryoma Y; Saito M; Sato M
J Immunother; 2004; 27(6):432-41. PubMed ID: 15534487
[TBL] [Abstract][Full Text] [Related]
8. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity.
Naito K; Ueda Y; Itoh T; Fuji N; Shimizu K; Yano Y; Yamamoto Y; Imura K; Kohara J; Iwamoto A; Shiozaki A; Tamai H; Shimizu T; Mazda O; Yamagishi H
Int J Oncol; 2006 Jun; 28(6):1481-9. PubMed ID: 16685449
[TBL] [Abstract][Full Text] [Related]
9. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer.
Li L; Wang W; Pan H; Ma G; Shi X; Xie H; Liu X; Ding Q; Zhou W; Wang S
J Transl Med; 2017 Jan; 15(1):23. PubMed ID: 28137271
[TBL] [Abstract][Full Text] [Related]
10. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.
Nakahara S; Tsunoda T; Baba T; Asabe S; Tahara H
Cancer Res; 2003 Jul; 63(14):4112-8. PubMed ID: 12874015
[TBL] [Abstract][Full Text] [Related]
12. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
13. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
16. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.
Koido S; Hara E; Homma S; Mitsunaga M; Takahara A; Nagasaki E; Kawahara H; Watanabe M; Toyama Y; Yanagisawa S; Kobayashi S; Yanaga K; Fujise K; Gong J; Tajiri H
J Immunol; 2007 Oct; 179(7):4874-83. PubMed ID: 17878387
[TBL] [Abstract][Full Text] [Related]
18. Improvement of a dendritic cell-based therapeutic cancer vaccine with components of Toxoplasma gondii.
Motamedi M; Arab S; Moazzeni SM; Khamis Abadi M; Hadjati J
Clin Vaccine Immunol; 2009 Oct; 16(10):1393-8. PubMed ID: 19656994
[TBL] [Abstract][Full Text] [Related]
19. Fusion hybrid of dendritic cells and engineered tumor cells expressing interleukin-12 induces type 1 immune responses against tumor.
Shi M; Su L; Hao S; Guo X; Xiang J
Tumori; 2005; 91(6):531-8. PubMed ID: 16457153
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
